Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis

Abstract Objective Eculizumab and ravulizumab are complement protein C5 inhibitors, showing efficacy and tolerability for patients with anti‐acetylcholine receptor‐positive (AChR+) generalized myasthenia gravis (gMG) in phase 3 clinical trials and subsequent analyses. The purpose of the present stud...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Daiki Tokuyasu, Shigeaki Suzuki, Akiyuki Uzawa, Yuriko Nagane, Masayuki Masuda, Shingo Konno, Tomoya Kubota, Makoto Samukawa, Takamichi Sugimoto, Kei Ishizuchi, Munenori Oyama, Manato Yasuda, Hiroyuki Akamine, Yosuke Onishi, Yasushi Suzuki, Naoki Kawaguchi, Naoya Minami, Takashi Kimura, Masanori P. Takahashi, Hiroyuki Murai, Kimiaki Utsugisawa
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2024-05-01
Colecção:	Annals of Clinical and Translational Neurology
Acesso em linha:	https://doi.org/10.1002/acn3.52051
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!